Live Breaking News & Updates on நரம்பியல் நிறுவனம் ஆஃப் தி உப்பு

Stay updated with breaking news from நரம்பியல் நிறுவனம் ஆஃப் தி உப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer's disease

Bruno Dubois
Bruno Dubois is currently Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital at Paris, University Pierre et Marie Curie Paris VI. He is Director of the Behavioural Neurology Department and of the Dementia Research Center at the Hospital. He is also Director of the Research Unit Inserm U-610 of the ICM (Institut du Cerveau et de la Moelle Epinière) of the Hospital. He is coordinator of the National Reference Center on Rare Dementias and of the National Reference Center for young-onset Alzheimer patients. He is President of the Scientific Committee of France-Alzheimer and of IFRAD (International Fund Raising for Alzheimer s disease), consultant for the Human Frontier Program and Expert of the French Agency of Drugs. He is a member of the European Alzheimer Disease Consortium (EADC). He has published on anatomical and biochemical studies on the central cholinergic systems in rodents and humans; on cognitive neuropharmacolo ....

Boston University , United States , France General , Los Angeles , City Of , United Kingdom , Noord Holland , Jeffrey Freedman , Bruno Dubois , Philip Scheltens , Las Vegas , Arthur Rouill , Deltaplan Dementie , Queen Square , Moelle Epini , Jeffreyl Cummings , Olivier Hermine , American Association Of Geriatric Psychiatry , Dementia Research Center , Board Of Trustees , Dutch Pearlstring Institute , University Hospital At Paris , Vu University Medical Center , Human Frontier Program , Brain Institute , Alzheimer Imaging Consortium ,

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer's disease Paris Stock Exchange:AB

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer's disease Paris Stock Exchange:AB
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Boston University , United States , France General , Los Angeles , City Of , United Kingdom , Noord Holland , Jeffrey Freedman , Bruno Dubois , Philip Scheltens , Las Vegas , Arthur Rouill , Deltaplan Dementie , Queen Square , Moelle Epini , Jeffreyl Cummings , Olivier Hermine , American Association Of Geriatric Psychiatry , Dementia Research Center , Board Of Trustees , Dutch Pearlstring Institute , University Hospital At Paris , Vu University Medical Center , Human Frontier Program , Brain Institute , Alzheimer Imaging Consortium ,

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer's disease – IT Business Net

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer's disease – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Boston University , United States , France General , Los Angeles , City Of , United Kingdom , Noord Holland , Jeffrey Freedman , Bruno Dubois , Philip Scheltens , Las Vegas , Arthur Rouill , Deltaplan Dementie , Queen Square , Moelle Epini , Jeffreyl Cummings , Olivier Hermine , American Association Of Geriatric Psychiatry , Dementia Research Center , Board Of Trustees , Dutch Pearlstring Institute , University Hospital At Paris , Vu University Medical Center , Human Frontier Program , Brain Institute , Alzheimer Imaging Consortium ,

AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer's disease met its primary endpoint

Share:
PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER S DISEASE MET ITS PRIMARY ENDPOINT
MASITINIB DEMONSTRATED SIGNIFICANT EFFECT ON BOTH COGNITION, MEASURED WITH ADAS-COG, AND DAILY ACTIVITY, MEASURED WITH ADCS-ADL
AB SCIENCE WILL HOST A LIVE WEBCAST ON DECEMBER 17, 2020 - 11am-12am EST; 5pm-6pm CET WITH KEY OPINION LEADERS TO FURTHER DISCUSS THE RESULTS
Paris, December 16, 2020, 8am CET
AB Science SA (Euronext - FR0010557264 - AB) today announced that the Phase 2B/3 study (AB09004 - NCT01872598) evaluating oral masitinib in patients with mild and moderate Alzheimer s disease met its predefined primary endpoint.
Study AB09004 was an international, randomized, placebo-controlled, phase 2B/3 study evaluating different doses of masitinib as a treatment of patients with confirmed mild to moderate Alzheimer s disease. This study compared the efficacy and safety of masitinib relative to placebo after 24 weeks of treatment when administered as an add-on ther ....

United States , Noord Holland , Boston University , France General , Los Angeles , City Of , United Kingdom , Scler Frontotemporal Degener , Jeffrey Freedman , Bruno Dubois , Philip Scheltens , Weili Xu , Alain Moussy , Las Vegas , Arthur Rouill , Deltaplan Dementie , Queen Square , Moelle Epini , Jeffreyl Cummings , Olivier Hermine , Dementia Research Center , American Association Of Geriatric Psychiatry , Board Of Trustees , Dutch Pearlstring Institute , University Hospital At Paris , Vu University Medical Center ,

AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer's disease met its primary endpoint Paris Stock Exchange:AB

PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER’S DISEASE MET ITS PRIMARY ENDPOINT
MASITINIB DEMONSTRATED SIGNIFICANT EFFECT ON BOTH COGNITION, MEASURED WITH ADAS-COG, AND DAILY ACTIVITY, MEASURED WITH ADCS-ADL
AB SCIENCE WILL HOST A LIVE WEBCAST ON DECEMBER 17, 2020 - 11am-12am EST; 5pm-6pm CET WITH KEY OPINION LEADERS TO FURTHER DISCUSS THE RESULTS
Paris, December 16, 2020, 8am CET
AB Science SA (Euronext - FR0010557264 - AB) today announced that the Phase 2B/3 study (AB09004 - NCT01872598) evaluating oral masitinib in patients with mild and moderate Alzheimer’s disease met its predefined primary endpoint.
Study AB09004 was an international, randomized, placebo-controlled, phase 2B/3 study evaluating different doses of masitinib as a treatment of patients with confirmed mild to moderate Alzheimer’s disease. This study compared the efficacy and safety of masitinib relative to placebo after 24 weeks of treatment when administered as an add-on therapy t ....

United States , Noord Holland , Boston University , France General , Los Angeles , City Of , United Kingdom , Scler Frontotemporal Degener , Jeffrey Freedman , Bruno Dubois , Philip Scheltens , Weili Xu , Alain Moussy , Las Vegas , Arthur Rouill , Deltaplan Dementie , Queen Square , Moelle Epini , Jeffreyl Cummings , Olivier Hermine , Dementia Research Center , American Association Of Geriatric Psychiatry , Board Of Trustees , Dutch Pearlstring Institute , University Hospital At Paris , Vu University Medical Center ,